Publicidad
Caso clínico 03 de agosto de 2024

Linfoma adrenal bilateral: Aporte de la imagen multimodal

Referenciar Imprimir Descargar PDF

Referencias

  1. McDonnell T, Mulkerrin E. Primary adrenal lymphoma. N Engl J Med 2021;384:165.
  2. Raoofziaee M, Yarmohamadi A, Ahmadnia H. Primary bilateral non-Hodgkin’s lymphoma of the adrenal gland. Indian J Urol 2018;34:300-2.
  3. Rashidi A, Fisher SI. Primary adrenal lymphoma: a systematic review. Ann Hematol 2013;92:1583-93.
  4. Horiguchi K, Hashimoto K, Hashizume M, et al. Primary bilateral adrenal diffuse large B-cell lymphoma demonstrating adrenal failure. Intern Med 2010;49:2241-6.
  5. Mozos A, Ye H, Chuang WY, et al. Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis. Mod Pathol 2009;22:1210-7.
  6. Kim SJ, Lee SW, Pak K, et al. Diagnostic accuracy of 18F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. Br J Radiol 2018;91:20170520
  7. Barat M, Cottereau AS, Gaujoux S, et al. Adrenal mass characterization in the era of quantitative imaging: State of the art. Cancers (Basel) 2022;14:569
  8. Karaosmanoglu AD, Onder O, Leblebici CB, et al. Cross-sectional imaging features of unusual adrenal lesions: a radiopathological correlation. Abdom Radiol 2021;46:3974-94.
  9. Yu K, Xue Q, Zhou F, et al. A novel diagnostic model for primary adrenal lymphoma. Front Endocrinol 2021;12:636-58.
  10. Evangelista L, Crimì F, Visentin A, et al. [18F]FDG PET/CT and PET/MR in patients with adrenal lymphoma: A systematic review of literature and a collection of cases. Curr Oncol 2022;29:7887-99.
  11. Elsayes KM, Emad-Eldin S, Morani AC, Jensen CT. Practical approach to adrenal imaging. Urol Clin North Am 2018;45:365-87.
  12. Elsayes KM, Mukundan G, Narra VR, et al. Adrenal masses: MR imaging features with pathologic correlation. RadioGraphics 2004;24(suppl-1):S73-86.
  13. Wang Y, Ren Y, Ma L, et al. Clinical features of 50 patients with primary adrenal lymphoma. Front Endocrinol 2020;11:595.
  14. Caoili EM, Korobkin M, Francis IR, et al. Adrenal Masses: Characterization with combined unenhanced and delayed enhanced CT. Radiology 2002;222:629-33.
  15. Blake MA, Cronin CG, Boland GW. Adrenal imaging. Am J Roentgenol 2010;194:1450-60.
  16. Park BK, Kim CK, Kim B, Lee JH. Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses. Radiology 2007;243:760-5.
  17. Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. RadioGraphics 2001;21:995-1012.
  18. Nandra G, Duxbury O, Patel P, et al. Technical and interpretive pitfalls in adrenal imaging. RadioGraphics 2020;40:1041-60.
  19. Mclean K, Lilienfeld H, Caracciolo JT, el al. Management of isolated adrenal lesions in cancer patients. Cancer Control 2011;18:113-26.
  20. Fujiyoshi F, Nakajo M, Fukukura Y, Tsuchimochi S. Characterization of adrenal tumors by chemical shift fast low-angle shot MR imaging: Comparison of four methods of quantitative evaluation. Am J Roentgenol 2003;180:1649-57.
  21. Miller FH, Wang Y, McCarthy RJ, et al. Utility of diffusion-weighted MRI in characterization of adrenal lesions. Am J Roentgenol 2010;194:W179-85.
  22. Haider MA, Ghai S, Jhaveri K, Lockwood G. Chemical shift MR imaging of hyperattenuating (>10 HU) adrenal masses: Does it still have a role? Radiology 2004;231:711-6.
  23. Sandrasegaran K, Patel AA, Ramaswamy R, et al. Characterization of adrenal masses with diffusion-weighted imaging. Am J Roentgenol 2011;197:132-8.
  24. Morani AC. Abdominal applications of diffusion-weighted magnetic resonance imaging: Where do we stand. World J Radiol 2013;5:68-80.
  25. Navin PJ, Moynagh MR. Optimal and novel imaging of the adrenal glands. Curr Opin Endocrinol Diabetes Obes 2022;29:253-62.
  26. Dong A, Cui Y, Wang Y, et al. (18)F-FDG PET/CT of adrenal lesions. Am J Roentgenol 2014;203:245-52.
  27. Kim YI, Cheon GJ, Paeng JC, et al. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma. Nucl Med Commun 2014;35:606-12.
  28. Ciftci E, Turgut B, Cakmakcilar A, Erturk SA. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions. Nucl Med Commun 2017;38:788-94.